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Abstract—An important objective of the INTEGRATE project1 is 
to build tools that support the efficient execution of post-genomic 
multi-centric clinical trials in breast cancer, which includes the 
automatic assessment of the eligibility of patients for available 
trials. The population suited to be enrolled in a trial is described 
by a set of free-text eligibility criteria that are both syntactically 
and semantically complex. At the same time, the assessment of 
the eligibility of a patient for a trial requires the (machine-
processable) understanding of the semantics of the eligibility 
criteria in order to further evaluate if the patient data available 
for example in the hospital EHR satisfies these criteria. This 
paper presents an analysis of the semantics of the clinical trial 
eligibility criteria based on relevant medical ontologies in the 
clinical research domain: SNOMED-CT, LOINC, MedDRA. We 
detect subsets of these widely-adopted ontologies that 
characterize the semantics of the eligibility criteria of trials in 
various clinical domains and compare these sets. Next, we 
evaluate the occurrence frequency of the concepts in the concrete 
case of breast cancer (which is our first application domain) in 
order to provide meaningful priorities for the task of 
binding/mapping these ontology concepts to the actual patient 
data. We further assess the effort required to extend our 
approach to new domains in terms of additional semantic 
mappings that need to be developed. 
Keywords-clinical trials, eligibility criteria, 
oncology, concepts, medical ontologies, SNOMED-CT, MedDRA, 
LOINC. 
I. INTRODUCTION 
The collaborative INTEGRATE project aims to support a 
novel research approach in oncology through the development 
of innovative biomedical infrastructures enabling 
1
 Driving excellence in Integrative Cancer Research through 
Innovative Biomedical Infrastructures, http://www.fp7-
integrate.eu/ 
multidisciplinary collaboration, management and large-scale 
sharing of multi-level data, and the development of new 
methodologies and of predictive multi-scale models in cancer. 
The INTEGRATE infrastructure will bring together 
heterogeneous multi-scale biomedical data generated through 
standard and novel technologies within post-genomic clinical 
trials and seamlessly link to existing research and clinical 
infrastructures, such as clinical trial systems, eCRFs, and 
hospital EHRs, in order to enable a range of innovative 
applications. 
The project also aims to make relevant steps towards 
semantic interoperability. To be able to reuse previous efforts 
in data sharing, modeling and knowledge generation, and to 
access relevant external sources of data and knowledge it is 
beneficial to adhere whenever possible to widely-accepted 
standards and ontologies. The use of standards will also 
support wide scale adoption of our solutions. 
An important objective of this project is to build tools that 
facilitate efficient the execution of post-genomic multi-centric 
clinical trials in breast cancer. A range of such tools aim to 
support recruitment through the automatic evaluation of the 
eligibility of patients for trials based on matching the 
characteristics of the patient population required by the trial to 
the patient data available for instance in the hospital EHR. 
Clinical trials are key instruments in clinical research that 
enable the validation of research hypotheses turning them into 
evidence that can be applied in wide clinical care. The 
population suitable to be enrolled in a trial is described by a set 
of free-text eligibility criteria that are both syntactically and 
semantically complex and whose automatic evaluation in order 
to assess the eligibility of a patient for a set of trials is a 
challenging task. 
As criteria describe characteristics of the eligible patient 
population that need to be matched against the data items that 
are known for an individual patient, this task would be 
facilitated by the ability to identify the semantic entities that 
sufficiently describe the meaning of the criteria and by 
establishing links to relevant available data, stored for instance 
in an EHR system. Building these links (mappings) is a 
partially manual process and it is beneficial to be able to reuse 
them whenever possible across trials and systems. 
This paper focuses on the analysis of the semantics of the 
eligibility criteria of clinical trials based on widely used 
medical ontologies. We identify the subsets of the ontologies 
that sufficiently capture the content of the eligibility criteria of 
trials in the clinical domain of interest which is breast cancer 
and compare with trials in cancers other than breast and in the 
cardiovascular domain. 
We evaluate whether our modular approach for the 
selection of the sets of concepts based on the clinical domain is 
scalable and feasible. Selecting subsets instead of using entire 
ontologies facilitates the linkage of the clinical trial criteria to 
the actual patient records. The definition of mappings or other 
processing steps for entire ontologies is not feasible because of 
the sizes of the ontologies. 
Our approach to identifying relevant subsets of ontologies 
relies on the annotation with ontology concepts of a large 
corpus of clinical trial eligibility criteria. We prioritize relevant 
concepts based on their frequency in the breast cancer subset 
and on their co-occunence in trials in other domains. 
II. THE SEMANTIC SOLUTION AND THE PATIENT 
RECRUITMENT APPLICATION 
At the centre of the semantic solution that links trial 
descriptions to the patient data is the core dataset as in [1]: 
Soundly defined and agreed-upon clinical structures consisting 
of standard-based concepts, their relationships, quantification 
etc., that together sufficiently describe the clinical domain. To 
maximize reuse we evaluate the ability of several ontologies to 
capture the semantics of the criteria. It is of interest to identify 
the subsets of the ontologies that cover the meaning of the 
criteria in relevant clinical domains, the sizes of these subsets, 
the frequencies of concepts across trials and the overlap 
between subsets that describe criteria of trials in different 
domains. This information enables us to evaluate the effort 
required for the implementation of mappings, the priorities in 
building these mappings and the scalability of our solution with 
the number of trials and the extensibility to other domains. 
We aim to capture the semantics of the clinical terms by 
standard terminology systems such as SNOMED-CT, 
MedDRA5 and LOINC6, which are widely used in the clinical 
domain. The scalability of the solution needs to be achieved by 
modularization, e.g. instead of aiming at inclusion of the 
complete SNOMED terminology we will identify a core subset 
that covers the chosen clinical domain and the datasets in our 
repositories. In the process of identifying the core dataset and 
the conesponding mapping tools, we need to allow for easy 
extension of this core dataset when the inclusion of new 
concepts becomes necessary (e.g. when adding new trials). 
The selection of this core dataset is both clinical domain-
and application-specific. Our first application area is clinical 
trial recruitment. To support automatic assessment of the 
suitability of patients for trials we need to be able to capture the 
semantics of the eligibility criteria and to evaluate if those are 
satisfied by the available patient data. 
After identifying the concepts that define the semantics of 
the criteria we need to bind those to the information model of 
the system containing the patient data. As the development of 
these mappings is a time consuming and partially manual 
process it is important to minimize the effort required. 
Therefore, we need to evaluate the sizes of the concept sets that 
are relevant and the ease of handling updates (e.g. adding new 
clinical trials, and incorporating changes/updates in the 
ontologies used or in the information models of the sources) 
and extensions to new clinical domains. These aspects are 
important to assess the feasibility of our solution. In this paper 
we try to answer some of these questions by evaluating the 
semantic content of the trial eligibility criteria based on widely-
used ontologies. 
III. DESCRIPTION OF THE EXPERIMENT AND OF THE 
DATASET 
In order to analyze the semantics of eligibility criteria of 
clinical trials we have selected a large set of trial descriptions 
out of those published on ClinicalTrials.gov, a service of the 
U.S. National Institute of Health. We have used 
ClinicalTrials.gov because this site is widely used by the 
clinical research community and the set of trials available is 
both comprehensive and representative for our applications. 
We selected trials from three clinical domains: breast 
cancer, cancer other than breast cancer, and heart and blood 
diseases. TABLE I. indicates the number of trials in each of the 
three domains. The breast cancer corpus was selected as 
relevant because it is the first domain for which we will 
implement our semantic solution and trial recruitment tools. 
The second corpus, clinical trials that study cancer other than 
breast cancer, and the third, trials that investigate heart and 
blood diseases, will enable us to compare the semantics of the 
different domains and to evaluate our modular approach and 
the extensibility to a new clinical domain. 
TABLE I. NUMBER OF TRIALS IN THE EVALUATION 
Clinical domain 
Breast cancer 
(BC) 
4232 
Cancer other than breast 
(CwoBC) 
6691 
Heart and 
blood diseases 
(HBD) 
12255 
We extracted the eligibility criteria from these sets of trials 
and used a state of the art annotator to identify the ontology 
concepts present in these criteria. The annotator is available at 
BioPortal2 and is developed by the National Center for 
Biomedical Ontology. The BioPortal annotation results include 
information such as the concept name, concept identifier and 
the UMLS3 semantic type of the concept. 
2
 http://bioportal.bioontology.org/ 
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The annotator allows the user to select out of a library of 
over 300 biomedical ontologies those that are relevant and 
should be used in the annotations. We have selected 
SNOMED-CT, MedDRA andLOINC. 
We extracted and analyzed the sets of ontology concepts 
that were found to link to items from the eligibility criteria of 
our selected collection of clinical trials and compared the result 
for the three clinical domains selected and the three medical 
ontologies. The results of this analysis are described in the next 
section. 
IV. EVALUATION RESULTS 
The first step in the analysis was to identify the sizes of the 
sets of concepts that describe the semantics of a domain and 
how much of the entire ontology they represent. Our modular 
approach to semantic linkage would not work if a large part of 
those ontologies is relevant for the trial criteria, for instance 
because implementing semantic mappings for a large ontology 
such as SNOMED-CT (over 311 000 concepts in 2011) 
requires a huge effort and would not be feasible for our 
application. 
Next, we have compared the subsets of concepts among the 
different domains and for the three ontologies to identify 
overlaps and extensions. This enables us to estimate the effort 
of implementing our solution for the initial domain of breast 
cancer and the ease of extending this solution to new domains. 
Another aspect of interest is to compare trials in each 
domain and assess how similar the semantics of distinct trials 
are. A large degree of similarity (which would be expected) 
means that once implementing our solution for a sufficiently 
large set of trials, adding new trials requires little effort. It is 
also relevant to prioritize the concepts that are occurring most 
often. 
Finally, we investigated the most frequent semantic types 
that correspond to the concepts identified in the criteria. This 
additional information is relevant as it enables us to classify 
concepts with similar content or from similar sources. 
A. Subsets of concepts 
The figures below compare the sets of relevant concepts for 
the three clinical domains and the three ontologies that we 
selected. In all cases the largest set is the one that is the overlap 
among the three domains, therefore concepts that are domain 
independent. The breast cancer corpus has a small subset that is 
specific for this disease (marked with "a" in the figure) and 
also relatively small subsets that constitute overlaps with each 
of the other domains. This makes our modular approach very 
feasible as a large amount of the concepts used in the semantic 
solution for breast cancer will be also relevant for other 
diseases. 
Extensions to new domains are also manageable as the 
additional sets of concepts are relatively small, even for 
completely different domains (e.g. extending from BC to 
HBD). This is especially the case for LOINC, where the 
module covering the concepts that are specific for HBD is half 
the size of the overlap with BC and CwoBC. 
Also in absolute numbers, the sizes of the sets of concepts 
that capture the semantics of our domains are reasonable and 
support the implementation of our semantic solution and of the 
trial recruitment applications that will rely on it. 
SNOMED-CT CwoBC 
BC 
HBD 
Subset 
a 
b 
c 
d 
e 
f 
9 
No. of concepts 
1251 
1312 
930 
6738 
2724 
2072 
6351 
Figure 1. Sets of SNOMED-CT concepts for breast cancer (BC), cancer 
other than breast cancer (CwoBC) and heart and blood disease (HBD) 
MedDRA CwoBC 
BC 
HBD 
Subset 
a 
b 
c 
d 
e 
f 
9 
No. of concepts 
351 
316 
228 
1458 
856 
557 
2120 
Figure 2. Sets of MedDRA concepts for breast cancer (BC), cancer other 
than breast cancer (CwoBC) and heart and blood disease (HBD 
LOINC CwoBC 
BC 
HBD 
Subset 
a 
b 
c 
d 
e 
f 
g 
No. of concepts 
191 
277 
201 
2495 
573 
516 
1123 
Figure 3. Sets of LOINC concepts for breast cancer (BC), cancer other than 
breast cancer (CwoBC) and heart and blood disease (HBD) 
Error! Reference source not found.indicates the ratio of 
the three selected ontologies that cover the semantics of our 
domains. It shows that a small percentage of the ontologies are 
sufficient to capture the content of the trial descriptions in the 
specific domains. For instance, in the case of breast cancer 
trials 3.2 % of SNOMED CT, 3.3% of MedDRA and 5.4% of 
LOINC were used in the annotation of our datasets. 
TABLE II. RATIO OF THE ONTOLOGIES THAT CAPTURE THE SEMANTICS 
OF THE THREE SETS OF CLINICAL TRIALS 
BC 
CwoBC 
HBD 
SNOMED-CT 
0.032 
0.041 
0.051 
MedDRA 
0.033 
0.045 
0.062 
LOINC 
0.054 
0.066 
0.074 
B. Reoccurrence of concepts across trials 
In this section we investigate the semantic similarity among 
trials. Intuitively we expected that trials will have a large ratio 
of criteria that are similar, but that new trials do introduce new 
concepts. This is confirmed by Figure 4. that depicts for the 
three corpuses of trials and the three ontologies the distribution 
of concepts across trials. Only the top most frequent concepts 
are depicted and each concept is counted once per trial. In all 
cases there is a relatively small group of concepts that occur in 
a large number of trials and there is another group of concepts 
that are rare or unique for specific trials. To further illustrate 
this, TABLE III. provides for each selected clinical domain and 
ontology the average number of trials in which a concept 
occurs, the average number of trials for the top 100 most 
frequent concepts, and the average number of trials for the top 
500 most frequent concepts. 
To have an additional reference, we have also counted the 
number of ontology concepts that occur per trial. In the case of 
breast cancer we have concluded that there are on average 199 
SNOMED-CT concepts per trial, 27 MedDRA concepts and 
108 LOINC concepts. 
These facts enable us to prioritize the implementation of 
semantic mappings starting with the concepts that occur often 
and demonstrate that the effort of adding new trials is low: 
Updates will be required, but the additional concepts that need 
to be mapped to relevant data are few. 
TABLE IV. and TABLE V. include examples of very 
frequent concepts of SNOMED-CT and MedDRA that occur in 
the BC dataset. 
t 
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Figure 4. The reoccurrence of concepts across trials. The number of BC, CwoBC and respectively HBD trials (y-axis) that include the top 500 most frequently 
occuring concepts (x-axis) out of SNOMED-CT, MedDRA and LOINC. Concepts were counted once per trial. 
TABLE III. STATISTICS OF THE REOCCURENCE OF ONTOLOGY CONCEPTS IN BREAST CANCER TRIALS 
Reoccurrence of ontology concepts for BC (4232 trials) 
Statistics 
Average number of trials for top 100 concepts 
Average number of trials for top 500 concepts 
Average number of trials for all unique concepts 
Number of distinct concepts 
Concepts occuring in a single trial 
SNOMED-CT 
1835.57 
756.63 
51.865 
10231 
3159 
MedDRA 
632.61 
163.01 
36.98 
2353 
815 
LOINC 
1597.45 
510.11 
89.31 
3164 
671 
TABLE IV. FREQUENT SNOMED-CT CONCEPTS IN BREAST CANCER TRIALS (ALL OCCURENCES COUNTED) 
Concept name 
Disease 
Neoplasm, malignant (primary) 
Entire breast 
Breast structure 
Therapeutic procedure 
Therapy 
Malignant neoplastic disease 
History of 
Study 
Malignant tumor of breast 
Antineoplastic chemotherapy regimen 
Drug therapy 
Concept code 
64572001 
86049000 
181131000 
76752008 
103733002 
276239002 
363346000 
392521001 
224699009 
254837009 
69960004 
182831000 
Number of occurrences 
13261 
11241 
10254 
10246 
9958 
9956 
9764 
8170 
7823 
5544 
5544 
5336 
TABLE V. FREQUENT MEDDRA CONCEPTS IN BREAST CANCER TRIALS (ALL OCCURENCES COUNTED) 
Concept name 
Cancer 
Breast cancer 
Chemotherapy 
Metastatic 
Carcinoma 
Surgery 
Radiotherapy 
Pregnant 
Metastases 
Creatinine 
Concept code 
10007050 
10006187 
10061758 
10027474 
10007284 
10042609 
10037794 
10036586 
10027476 
10011358 
Number of occurrences 
9737 
6133 
5320 
3689 
2759 
2739 
2612 
2148 
2109 
1956 
C. Semantic types 
In this section we evaluate the UMLS semantic types of the 
concepts in our datasets as they can provide additional 
information about the semantics of the criteria and identify 
concepts that are similar. We compare the frequency in the sets 
of concepts of several semantic types that are relevant for our 
application domain. We have annotated with semantic types all 
the concepts identified in all three ontologies. 
The tables below depict the most frequent semantic types 
for the three corpuses: BC, CwoBC and HBD. We can observe 
that there are little differences among the clinical domains in 
the hierarchy of semantic types to which most of the concepts 
belong. 
TABLE VI. RATIO OF THE MOST FREQUENT UMLS SEMANTIC TYPES FOR 
THE BC DATASET (RELATIVE TO TOTAL NUMBER OF CONCEPTS) 
Semantic type 
Neoplastic Process 
Qualitative Concept 
Therapeutic or Preventive Procedure 
Body Part, Organ, or Organ Component 
Laboratory Procedure 
Finding 
Pharmacologic Substance 
Diagnostic Procedure 
Quantitative Concept 
Spatial Concept 
Ratio 
0.055 
0.041 
0.039 
0.031 
0.023 
0.018 
0.012 
0.010 
0.006 
0.005 
TABLE VII. RATIO OF THE MOST FREQUENT UMLS SEMANTIC TYPES FOR 
THE CWOBC DATASET (RELATIVE TO TOTAL NUMBER OF CONCEPTS) 
Semantic type 
Qualitative Concept 
Therapeutic or Preventive Procedure 
Neoplastic Process 
Laboratory Procedure 
Body Part, Organ, or Organ Component 
Finding 
Diagnostic Procedure 
Pharmacologic Substance 
Quantitative Concept 
Spatial Concept 
Ratio 
0.080 
0.076 
0.065 
0.049 
0.041 
0.032 
0.022 
0.022 
0.012 
0.010 
TABLE VIII. RATIO OF THE MOST FREQUENT UMLS SEMANTIC TYPES FOR 
THE HBD DATASET (RELATIVE TO TOTAL NUMBER OF CONCEPTS) 
Semantic type 
Therapeutic or Preventive Procedure 
Semantic type 
Qualitative Concept 
Body Part, Organ, or Organ Component 
Finding 
Laboratory Procedure 
Pharmacologic Substance 
Diagnostic Procedure 
Quantitative Concept 
Spatial Concept 
Sign or Symptom 
Ratio 
0.041 
0.038 
0.036 
0.029 
0.020 
0.018 
0.015 
0.011 
0.010 
V. RELATED WORK 
In this paper we focus on clinical trials in breast cancer and 
present an analysis of the semantics of the eligibility criteria of 
trials based on widely-adopted medical ontologies: SNOMED-
CT4, MedDRA5 and LOINC6. 
SNOMED-CT (Systematized Nomenclature of Medicine-
Clinical Terms) is a clinical vocabulary focused on accurately 
recording health care encounters and the associated electronic 
health information exchange. Although SNOMED-CT is 
sometimes criticized, it has a significant uptake in clinical 
practice, such as its use in HL77 messaging. MedDRA focuses 
on the regulatory process of drug development and is a medical 
vocabulary that is used by regulatory bodies and the regulated 
biopharmaceutical industry for data entry, retrieval, evaluation 
and display. MedDRA is used in clinical trials for reporting 
adverse events. LOINC (Logical Observation Identifiers 
Names and Codes) has the purpose to facilitate the exchange 
and pooling of results for clinical care, outcomes management, 
and research. LOINC provides universal identifiers for 
laboratory and other clinical observations and it is a preferred 
code set for HL7 for laboratory test names in transactions 
between health care facilities, laboratories, laboratory testing 
devices, and public health authorities. 
With respect to the selection of domain-specific parts of 
ontologies, in [2] the subset of UMLS that is relevant to 
describe breast cancer treatment was identified in order to 
facilitate the development of clinical decision support systems. 
While the general idea is comparable, the purpose and the 
method were different. As background knowledge the concepts 
from medical guidelines were used, considered at the decision 
points of selecting a suitable treatment for a patient. The 
guideline concepts were manually mapped to the SNOMED-
CT concepts and the subset obtained was automatically 
expanded via the ontology hierarchy and the UMLS semantic 
network. 
A significant body of research has focused on the general 
problem of formalization of eligibility criteria and on 
Ratio 
0.044 
' http://www.ihtsdo.org/SNOMED CT/ 
5
 http://www.meddramsso.com 
6
 http://loinc.org/ 
7
 http://www.hl7.org/ 
recruitment for clinical trials, including (semi)-automatic trial 
matching. In [3] an extensive overview of existing solutions 
and approaches is provided. In previous work [4] we have 
analyzed the eligibility criteria of clinical trials and we have 
identified relevant syntactic patterns that occur in trial criteria. 
These patterns are modifiers that provide the context of the 
criterion and while they do not express the semantics of the 
criterion and cannot be linked to actual patient data for 
evaluation of eligibility, they provide the context of the 
criterion. We have evaluated the coverage of these patterns for 
a large set of eligibility criteria and their expressivity. 
In [5] we evaluate the approach to eligibility criteria 
formalization, with the focus on pattern detection. The 
feasibility is influenced by the number of patterns, the 
algorithm of patterns detection, and the restrictiveness and the 
variety of synonym forms covered by the regular expressions. 
We conclude that the algorithm of patterns detection has 
sufficient precision and recall to support, in most cases, the 
generation of correct corresponding queries and to determine 
patient eligibility. The broad range of defined patterns allows 
automatic interpretation of even complex eligibility criteria. 
In [6] an analysis has been carried out to estimate the 
coverage provided by SNOMED-CT for clinical research 
concepts that represented by the items present on case report 
forms (CRFs). The authors also evaluated the semantic nature 
of those concepts relevant to post-coordination methods. The 
dataset included a total of 17 CRFs developed by 
rheumatologists conducting several longitudinal, observational 
studies in the clinical domain of vasculitis. From the CRFs a 
total set of 616 (unique) items were identified. Each unique 
data item was classified as either a clinical finding or 
procedure. The items were coded by the presence and nature of 
SNOMED CT coverage and manually classified into semantic 
types by 2 coders. 
In [1] we introduce a scalable, modular and pragmatic 
approach to achieving semantic interoperability. We believe 
that interoperability in healthcare can be achieved gradually on 
specific domains and by making use whenever possible of 
existing standards. This is also the approach that we take in the 
INTEGRATE project for a well-defined clinical domain which 
is clinical trials in breast cancer. As presented in this paper, we 
identify those modules of ontologies that are relevant in this 
domain and in our semantic solution we will implement 
mappings for those specific concepts. This facilitates efficient 
further extensions to other domains of relevance and easy reuse 
of tools. A gradual approach to interoperability is well 
supported in literature. In [7] it is stated that "regardless of the 
type of vision one may develop, semantic interoperability is not 
a phenomenon to be expected over night". The group of 
experts conclude that semantic interoperability in healthcare 
requires a large number of changes at both the technical and the 
use case level, and that even in that vision no full semantic 
interoperability or a complete harmonization of either EHR 
models or terminologies can be expected. 
VI. CONCLUSIONS 
This paper has focused on the evaluation of the semantics 
of the eligibility criteria of clinical trials in terms of identifying 
relevant ontology concepts that express the content of the 
criteria. In the context of developing applications supporting 
efficient execution of clinical trials it is essential to assess 
whether our modular semantic linkage approach is applicable 
to this domain. This requires to decide whether the semantics 
of the eligibility criteria can be captured by widely-used 
medical ontologies and to estimate the effort required to 
semantically link the eligibility criteria to the relevant patient 
data (for example preserved in an EHR) to enable the decision 
of whether the patient satisfies the criteria. 
The ontologies selected were SNOMED-CT, MedDRA and 
LOINC which are widely used in the clinical domain and when 
used by our solutions could support scalability and adoption. 
We have identified the relevant subsets of these ontologies that 
capture the semantics of the eligibility criteria of clinical trials 
in selected clinical domains. 
Another important question we have answered is of 
extendibility. Our main focus in the INTEGRATE project is 
breast cancer, but we aim to design solutions that can be 
extended and applied to other clinical domains. Therefore we 
evaluated and compared the sets of concepts that capture the 
semantics of different clinical domains: breast cancer, cancer 
other than breast cancer, and heart and blood disease. 
The analysis of the concepts that are specific to a domain or 
occur across various domains let us modularize the sets of 
concepts that are relevant for a particular group of trials. We 
identified the subset of concepts that exclusively occur in 
eligibility criteria related to one of the three domains, those that 
are shared among trials in various clinical domains. 
We have relied on the annotation of a large collection of 
clinical trials using the NCBO's BioPortal annotator. Our 
findings indicate that relatively small subsets (in terms of 
number of concepts) of the ontologies are required to capture 
the semantics of the eligibility criteria. It was also shown that 
the semantic overlap among clinical domains is very large for 
all ontologies considered, therefore once developed for a 
particular domain a large part of the mappings can be reused 
when extending the solution to a new domain. The additional 
sets of concepts that are specific to those domains are relatively 
small and the implementation of the new mappings is feasible. 
The frequency of the concepts, their reoccurrence across 
various trials and their uniqueness for particular types of trials 
informs the selection of the concept sets that cover the meaning 
of the criteria. These statistics guide the process of linking the 
concepts to the data items in the patient records by building the 
necessary mappings. 
We have concluded that the reuse of concepts across trials 
is very significant, with a relatively small number of concepts 
that occur in many trials. Therefore, they can be prioritized in 
the implementation of mappings. We can capture a large part 
of the semantics of the trials with a relatively small number of 
concepts that sufficiently describe the content of the eligibility 
criteria. 
The infrequent concepts that are specific to single trials are 
also manageable and it is most efficient for the implementation 
of the semantic solution to only add those when a trial 
containing them is entered into the system. The long tail of the 
graph indicates that the sets of concepts identified will not be 
complete and will grow with new trials, but the high overlap 
across trials makes the effort of handling updates for new trials 
low. 
We have also evaluated the UMLS semantic types of the 
concepts as these can provide additional hints about the 
semantics of the criteria and can be used in the semantic 
solution to reason about the criteria at a higher level of 
abstraction. We compared the frequency in the sets of concepts 
of several semantic types that are relevant for our application 
domain. 
In our future work we will assess the coverage of our 
domain of interest by the sets of concepts, identify and address 
limitations (post-coordinated terms in SNOMED, criteria not 
covered by any concept, etc.), and develop the necessary 
mappings between the clinical trial criteria and our HL7 RIM-
based patient data model. 
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